share_log

SIGA Technologies Shares Are Trading Lower After Interim Results From the STOMP Study Showed That Tecovirimat Did Not Improve the Time to Lesion Resolution Compared to Placebo in Adults With Mild to Moderate Clade II Mpox.

Benzinga ·  Dec 11, 2024 05:02
SIGA Technologies Shares Are Trading Lower After Interim Results From the STOMP Study Showed That Tecovirimat Did Not Improve the Time to Lesion Resolution Compared to Placebo in Adults With Mild to Moderate Clade II Mpox.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment